Trial Profile
Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2014
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors BioGeneriX; Teva Pharmaceutical Industries
- 18 Nov 2013 According to the Teva Pharmaceuticals media release, the safety of Filgrastim [Granix] was evaluated in this trial and another two phase III trial in patients receiving myelosuppressive chemotherapy.
- 07 Jul 2011 New trial record